Molecular You is pleased to announce that the company has signed a Memorandum of Understanding (MOU) with NKCL Bio Group, a leading South Korean biotechnology company that develops immune cell therapies utilizing natural killer (NK) cells. These cells are responsible for directly identifying and destroying cancer cells and other abnormal cells.
Molecular You’s AI-assisted platform analyzes more than 280 blood-based biomarkers to predict health risks before symptoms appear, providing clear action plans to reduce them for diseases such as cancer, dementia, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, and more.
As part of the collaboration, Molecular You and NKCL will also develop an AI-based bio-healthcare big data platform that merges Molecular You’s molecular datasets with NKCL’s immune cell therapy data to improve disease prediction and underpin the development of personalized treatment methods. By integrating these predictive insights with NKCL’s NK cell therapies, the partnership creates an end-to-end solution:
- Early detection of diseases such as cancer and dementia
- Personalized treatment guided by molecular insights
- Continuous monitoring of treatment outcomes
This approach moves beyond reactive medicine to deliver comprehensive prevention, early diagnosis, and optimized therapy, thereby reducing healthcare costs, easing patient suffering, and improving long-term outcomes.
The collaboration marks Molecular You’s first commercial deployment in Asia, establishing South Korea as a launchpad for international expansion in the Asian markets.
Through a third-party overseas investment institution, the companies have also secured a USD 35 million investment into NKCL, which will accelerate both NKCL’s NK cell therapy development and the adoption of Molecular You’s platform in clinical practice.
“By partnering with a leading healthcare innovator such as NKCL, Molecular You is deploying a new go-to-market channel in a new market, embedding itself into the local healthcare ecosystem, and co-anchoring platform adoption with strategic investment,” said Dr. Rob Fraser, President and Chief Scientific Officer of Molecular You. “This is a model we can now replicate across Asia and globally.”
His joint initiative will not only strengthen Korea’s biotechnology ecosystem but also establish a scalable model for predictive and precision health innovation in other international markets.
Read the Full Press Release from KNCL Online Here.
View Similar Articles